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Abstract
Objective: This literature review and meta-analysis was performed to evaluate the correlations
among hearing and vestibular clinical symptoms, temporal bone findings, and pathological
mechanisms in patients with systemic lupus erythematosus (SLE).
Study design: Relevant papers in the literature were retrospectively reviewed. Clinical hearing
aspects in patients with SLE and relevant temporal bone studies in the same field were analyzed.
Methods: PubMed and Google Scholar searches were performed using the following keywords:
‘‘auto-immune disease,’’ ‘‘systemic lupus erythematosus (SLE),’’ ‘‘hearing loss,’’ ‘‘temporal bone
study,’’ ‘‘vertigo,’’ ‘‘dizziness,’’ ‘‘tinnitus,’’ ‘‘ear symptoms,’’ ‘‘treatment,’’ ‘‘diagnosis,’’ ‘‘symptoms,’’
‘‘etiopathogenesis,’’ ‘‘Wegener granulomatosis,’’ ‘‘Sjogren,’’ ‘‘polyarteritis nodosa,’’ ‘‘Cogan syn-
drome,’’ and ‘‘granulomatosis.’’ Also included were reviews in which the following terms were
present: ‘‘SLE,’’ ‘‘temporal bone,’’ and ‘‘hearing symptoms.’’
Review and conclusion: This literature review and meta-analysis focused on the pathological
mechanisms through which SLE can damage inner ear structures and determinate hearing and
vestibular symptoms. The main mechanisms involved in inner ear damage include the autoimmune
response, deposition of immune complexes in the vessels and, to a lesser extent, cytotoxic
damage.
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Introduction
Systemic lupus erythematosus (SLE) is an
autoimmune disease with multiorgan
involvement and an incidence of 12.5–39.0
per 100,000 people in the general popula-
tion. The incidence of SLE is higher in
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women (82%–96%) than in men (4%–
18%),1–2 and it is two to three times more
prevalent in people of African and Asian
descent than those of European one.3 Onset
is most frequent from 20 to 39 years of age.4
SLE is a multifactorial pathology with
different aetiologies, including genetic chromo-
some alterations, inflammation, drugs, envir-
onmental factors, and interactions between the
adaptive and innate immune systems.1–3
The hallmark of SLE is the production of
autoantibodies that react with self-nuclear
and cytoplasmic antigens and culminate
in immunologic attacks on body organs,
resulting in tissue inflammation and multi-
organ damage.4 T- and B-lymphocyte
disorder plays a central role in this auto-
immune dysfunction.5 The role of natural
killer T cells has also been explored.6,7
Autoantibodies are directed toward antigens
at the nuclear cell level; one of the most
relevant antigens in SLE is double-stranded
DNA. Antibody-mediated attacks \ primarily
involve tissues and cells; however, they also
target the walls of blood vessels, resulting in a
generalized vascular alteration defined as
vasculitis.8
As a systemic disease, SLE can involve
different organs including the skin, kidney,
neurologic system, and musculoskeletal
system. Recent studies have also shown
involvement of the inner ear.9 The aim of
this study was to review the current litera-
ture with respect to hearing disorders in
patients with SLE and evaluate the correl-
ations among the pathophysiology, clinical
symptoms, and temporal bone findings
of SLE.
Material and methods
A systematic review was conducted by
searching PubMed and Google Scholar.
The following keywords were used to iden-
tify relevant articles: ‘‘autoimmune disease,’’
systemic lupus erythematosus (SLE),’’
‘‘hearing loss,’’ ‘‘temporal bone study,’’
‘‘vertigo,’’ ‘‘dizziness,’’ ‘‘tinnitus,’’ ‘‘ear
symptoms,’’ ‘‘treatment,’’ ‘‘diagnosis,’’
‘‘symptoms,’’ ‘‘etiopathogenesis,’’ ‘‘Wegener
granulomatosis,’’ ‘‘Sjogren,’’ ‘‘polyarteritis
nodosa,’’ ‘‘Cogan syndrome,’’ and ‘‘granulo-
matosis.’’ Studies in which the following
words were present were included in the
review: ‘‘SLE,’’ ‘‘temporal bone,’’ and
‘‘hearing symptoms.’’
Table 1 summarizes the collected data
for each publication selected for inclusion in
the review. In total, 49 articles were
reviewed.
Audiovestibular disorders
in patients with SLE
Clinical findings
SLE is characterized by the participation of
multiple antibodies in immune-mediated
tissue injury in different tissues and organs,
including the auditory system. At this level,
there are several mechanisms by which
antibodies may damage the inner ear: 1)
humoral-type antibody attacks on inner ear
antigens, 2) cell-mediated cytotoxic damage
to cochlear and vestibular hair cells, and 3)
immune-complex deposition in the micro-
vessels of the inner ear.5
The most common otologic symptom
found in clinical studies of patients with
SLE is sensorineural hearing loss (SNHL),
the reported prevalence of which ranges
from 6% to 70%.10–16 Table 2 summarizes
Table 1. Study collection data.
Author Audiogram
Type of article Type of hearing loss
Year of publication Cytocochleogram
Number of patients Description of bone
preparation
Systemic diseases Involved ear structures
Therapy used Middle ear aspect
Otologic symptoms Inner ear aspect
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the different subtypes of hearing loss found
in patients with SLE in multiple studies
performed from 1995 to 2013 (Table 2).
Various authors have reported different
pathways of SNHL in patients affected by
SLE: hearing loss may either be slowly
progressive or acute. It mainly affects high
frequencies, mimicking the typical presby-
cusis pattern; however, it may also affect the
low and middle frequencies. Maciaszczyk
et al.10 described progressive SNHL invol-
ving all frequencies except 500, 2000, and
4000Hz; Roverano et al.,12 in a series of 31
patients, identified asymptomatic bilateral
SNHL affecting high frequencies. Khalidi
et al.9 reported unilateral SNHL involving
500, 1000, 2000, and 3000Hz associated
with a 16% word discrimination score as
demonstrated by speech audiometry.
Sperling et al.,13 in a series of 84 patients,
described bilateral and slowly progressive
hearing loss; the same author in a previous
paper described patients with SLE who
developed sudden unilateral SNHL.
Table 2. Summary of hearing loss results.
Authors Patients (n) Year
Auditory
symptoms Hearing thresholds
Kataoka et al.37 2 1995 n/a Bilateral fluctuant SNHL
Sperling et al.13 84 1998 31.0% Unilateral SNHL (15%), bilateral
SNHL (17%)
Green and Miller15 1 2001 n/a Sudden pantonal unilateral
SNHL, male
Digiovanni and Nair14 1 2006 n/a Sudden unilateral SNHL for 3000
and 4000Hz; male
Roverano et al.12 31 2006 70.0% Bilateral symmetric SNHL for
2000, 4000, and 8000Hz
Gomides et al.19 45 2007 55.5% SNHL for all frequencies (14%);
SNHL for 500, 1000, and
2000Hz (57%); SNHL for
4000 and 8000Hz (28%)
Khalidi et al.9 1 2008 n/a Profound bilateral SNHL for 500,
1000, 2000, and 3000Hz;
female
Maciaszczyk et al.10 35 2011 71.4% Progressive SNHL with 500-,
2000-, and 4000-Hz frequency
preservation
Abbasi et al.11 45 2013 26.7% SNHL (11.1%), otorrhea (8.9%),
tinnitus (6.7%)
Lin et al.2 7168 2013 n/a Higher incidence of SNHL in
women aged 34 years. Most
frequently affected frequen-
cies: 4000 and 8000Hz
Chawki et al.17 1 2016 n/a Sudden bilateral hearing loss for
all frequencies (40 dB in right
ear, 60 dB in left ear)
Lasso de la Vega et al.16 55 2016 70.0% High-frequency hearing loss at
8000 and 18,000Hz
SNHL, sensorineural hearing loss; n/a, not available
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Digiovanni and Nair14 and Green and
Miller15 presented case reports of sudden
hearing loss in patients affected by SLE; in
contrast, Andonopoulos et al.17 showed that
the threshold of SNHL in patients with SLE
mimics the presbycusis pattern. In a large
population-based, retrospective cohort
study from the Taiwan National Health
Insurance Research Database, Lin et al.2
identified a higher prevalence of sudden
SNHL in patients with SLE, especially
young women, than in the general popula-
tion; the most common audiological pattern
was loss of high-frequency hearing in
women aged <35 years. These results were
in accordance with the findings by
Vendelman et al.,18 who reported bilateral
SNHL in patients affected by lupus,
hypothesizing a role of vasculitis of the
internal auditory artery and stria vascularis.
Chawki et al.19 recently presented a case
involving a young woman with SLE and
bilateral SNHL affecting the 250- to 8000-
Hz frequencies. In all studies, the most
commonly involved frequencies were in the
4000- to 8000-Hz range (65%), followed by
middle frequencies (32%) and low frequencies
(3%). The distribution of hearing loss by
frequency is shown in Figure 1.
Besides hearing loss, other audiovestibular
symptoms often associated with SLE include
tinnitus and vertigo. Tinnitus, a symptom
that can be linked to numerous condi-
tions,20–22 has been reported in patients
with SLE by Gomides et al.,21 Sperling
et al.,13 Dayal and Ellman,20 and Abbasi
et al.11 In all cases, tinnitus was associated
with hearing loss and may have been a
consequence of deafferentation. The ves-
tibular system appears to be involved in
SLE, although to a lesser extent; vertigo and
dizziness have rarely been reported in
patients with lupus. A few authors22,23
have described vertigo in patients with SLE
and, in all cases, this symptom was always
associated with SNHL or tinnitus. Gad and
Abdelateef24 found that vertigo in children
with SLE was always associated with coch-
lear symptoms. However, the incidence of
vestibular symptoms may be under-reported
due to the slowly progressive onset of these
symptoms and compensation by the som-
atosensory system and vision.
Temporal bone findings
Fourteen publications in which the authors
analyzed the effects of different autoimmune
diseases on inner ear structures were identi-
fied using the following keywords: ‘‘auto-
immune disease,’’ ‘‘systemic lupus erythe-
matosus (SLE),’’ ‘‘hearing loss,’’ ‘‘temporal
bone study,’’ ‘‘vertigo,’’ ‘‘dizziness,’’ ‘‘tin-
nitus,’’ ‘‘ear symptoms,’’ ‘‘treatment,’’
‘‘diagnosis,’’ ‘‘symptoms,’’ ‘‘etiopatho-
genesis,’’ ‘‘Wegener granulomatosis,’’
‘‘Sjogren,’’ ‘‘polyarteritis nodosa,’’ ‘‘Cogan
syndrome,’’ and ‘‘granulomatosis.’’ Only
studies in which the following words were
present were included in the review: ‘‘SLE,’’
‘‘temporal bone,’’ and ‘‘hearing symptoms.’’
Of these studies, 6 analyzed the effect of SLE
on the inner ear among a total of 52
analyzed specimens and were selected for
the present meta-analysis. The numbers of
specimens studied according to autoimmune
Figure 1. Hearing loss distribution in patients
affected by systemic lupus erythematosus.
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disease is summarized in Table 3. The
different percentages of autoimmune dis-
eases found in the analyzed specimens are
shown in Figure 2.
In total, 52 temporal bones, the ones
affected by SLE, were included in our meta-
analysis. Table 4 summarizes the symptoms
that the patients presented before death. The
most common condition was hearing loss,
found in>70% of patients. Hearing loss was
sensorineural in 96% of patients and mixed
in 4%. Vertigo and dizziness were reported
in 30% of patients. These data are consistent
Figure 2. Autoimmune disease and temporal bone specimens.
Table 3. Numbers of specimens studied according
to autoimmune disease.
Autoimmune disease
Specimens
studied (n)
Systemic lupus erythematosus 52
Granulomatosis with polyangiitis
(Wegener’s)
22
Polyarteritis nodosa 20
Sjogren syndrome 8
Cogan syndrome 7
Autoimmune hearing loss 4
Total 113
Table 4. Temporal bone analysis: symptoms
reported by patients before death.
Hearing and vestibular symptoms Percentage
Sensorineural hearing loss 96%
Mixed hearing loss 4%
Vertigo and dizziness 30%
Tinnitus 8%
Aural fullness 2%
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Figure 3. Pathophysiological findings in temporal bone specimens.
Figure 4. Main findings in cochlear and vestibular structures in temporal bone specimens.
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with those reported in the clinical studies
described in the previous paragraph. With
respect to histopathological findings, poly-
morphonuclear infiltration (31%) and vascu-
litis (27%) were the most common, followed
by fibro-osseous reaction (21%), new bone
formation (17%), and granulation (4%)
(Figure 3).
A deeper analysis of cochlear structures
showed moderate to severe inner hair cell
damage and, mainly, outer hair cell damage
in a large portion of studied temporal bones;
alterations involved the middle and apical
turns of the cochlea in most of the stu-
dies,25–28 and all turns were involved in one
study.27 Stria vascularis atrophy (33%) and
spiral ganglion degeneration (23%) were
two other consistent findings. Cochlear
hydrops was the least frequently identified
histopathological finding (Figure 4a). When
focusing on the vestibular system, type I
vestibular hair cell damage was the most
common finding (29% of cases),28 followed
by vestibular fibrosis (6%) and hydrops
(4%) (Figure 4b).
Pathophysiology of inner
ear involvement in SLE
SLE can damage tissues and organs through
three different mechanisms: 1) antibody/
antigen direct reactions, 2) cytotoxic action,
and 3) immune complex deposition. These
mechanisms represent the basis of inner
ear damage in patients with SLE, and a
schematic of their connection with specific
hearing and vestibular disorders is summar-
ized in Table 5.
The autoantibodies produced in patients
with SLE are mainly anti-DNA antibodies;
their effect changes the DNA conformation,
modifying the resultant protein produc-
tion and inducing apoptosis in cochlear
and vestibular hair cells and in the spiral
ganglion. In 1988, Barna and Hughes31
identified increased antibody activity in the
perilymph of patients with SLE; further-
more, this higher concentration of antibo-
dies increased the protein concentration.
These authors also reported that antibodies
circulating in the perilymph were associated
with the action of cytotoxic molecules and
induced a variation in endolymph proteins
strictly linked to hair cell degeneration.31
Immune complex deposition plays a cen-
tral role in the development of inner ear
vasculitis and is associated with atrophy of
the stria vascularis. Immune complex depos-
ition in the auditory artery reduces the vessel
calibre with a consequent decrease in blood
flow. This blood flow reduction induces
an oxygen deficit followed by the release
of oxidative molecules responsible for
damage to the hair cells10,11,32,33 and spiral
ganglion.34,37 In addition, the progressive
reduction of the vessel calibre increases
the resistance in the circulatory system,
eventually increasing the blood pressure
Table 5. Correlations among hearing disorders, temporal bone analysis, and physiopathological
mechanisms.
Hearing and vestibular symptoms Temporal bone findings Physiopathological mechanisms
Hearing loss and tinnitus Hair cell damage Anti-DNA antibodies
Cytotoxic damage
Variation of perilymph concentration
Spiral ganglion Degeneration Anti-DNA antibodies
Stria vascularis atrophy Immune complex deposition
Vertigo and dizziness Type I hair cell damage Anti-DNA antibodies
Cytotoxic damage
Variation of perilymph concentration
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and contributing to damage and fibrosis of
the stria vascularis as shown by the temporal
bone findings.35
Sudden hearing loss in patients with SLE
can be explained by a temporary blood
flow reduction in the inner ear, with com-
plete or partial recovery after restoration of
normal perfusion. Instead, recurrent vascu-
litis permanently damages the structure of
the ear because of the chronic oxygen def-
icit.30 Vasculitis appears to be the major
factor involved in cochlear and vestibular
damage.2,12,13,25,36,37
Green and Miller,15 Karatas et al.,22
Gazquez et al.,38 and Kataoka et al.39 sup-
ported the hypothesis that the antibody
mechanism can explain cochlear and vestibu-
lar hydrops and related hearing/vestibular
disorders. However, hydrops seems to be the
least common finding in patients with SLE
reported in the literature.
Treatment of hearing and
vestibular disorders in SLE
Different treatments for SLE-related hear-
ing disorders have been proposed in the
literature. These treatments are mainly
focused on prevention, especially for slowly
progressive hearing loss, and hearing restor-
ation for cases of sudden hearing loss.
Corticosteroid therapy is themost prevalent
therapy for sudden hearing loss and for the
prevention of further worsening of progressive
hearing loss in patients with SLE.11,37,40–43
Sudden hearing loss, as widely reported in the
literature, is also subject to spontaneous recov-
ery; Digiovanni and Nair14 reported a case of
spontaneous recovery of sudden hearing loss
in a patient with SLE.
Other treatments of hearing disorders in
patients with SLE include plasmapheresis as
reported by Kobayashi et al.44 and
Sichkareva et al.,45 anticoagulant therapy,15
and cyclophosphamide.46 These drugs
mainly contribute to a reduction in the
progression of SNHL.
More recently, the use of monoclonal
antibodies such as rituximab or alemtuzu-
mab has been proposed in SLE treatment.47
The suppressive effects of the immune
system are able to consistently reduce acti-
vation of the inflammatory mechanisms that
underlie inner ear damage.
Identification of the pathogenic mechan-
isms at the basis of audiovestibular symp-
toms in patients with SLE is crucial for
selection of the correct treatment.48–49
Steroids have different activities: anti-
inflammatory, immunosuppressive, and
anti-oedema effects. Immunosuppression
reduces the formation of immune com-
plexes, while anti-inflammatory and anti-
oedema actions restore the normal caliber of
affected vessels. Additionally, corticosteroid
therapy increases blood pressure as a side
effect; however, this has a therapeutic effect
in patients with SLE because high systemic
blood pressure increases blood flow in all
structures, including the auditory artery,
thus improving the oxygen concentration.
Plasmapheresis also improves the oxygen
concentration in the inner ear; and anti-
coagulant therapy improves blood fluidity by
increasing vascularization in smaller vessels
that have a reduced calibre secondary to SLE.
Immunosuppressant drugs such as cyclophos-
phamide reduce autoimmune activity and the
formation of immune complexes.
In the authors’ opinion, corticosteroids
should be considered as the first treatment
option to restore hearing in patients with
sudden hearing loss and prevent worsening
of progressive hearing loss in patients with
SLE because of the large availability of these
drugs worldwide and their much lower cost
compared with monoclonal antibodies.
In patients with progressive hearing loss,
cyclophosphamide should be used if steroid
therapy is unsuccessful. Plasmapheresis and
anticoagulant treatments can be useful
for the prevention of sudden hearing loss
and treatment of tinnitus and vestibular
symptoms; however, their use should be
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carefully evaluated on an individual basis
depending on the patient’s systemic involve-
ment and SLE history. Monoclonal anti-
bodies can be a valid choice, especially for
aggressive forms of SLE or in patients with
proven resistance to other treatments.
Conclusion
The temporal bone studies examined in the
present review confirm the aetiopathological
mechanisms of SLE in inner ear structures.
Two mechanisms are undoubtedly involved
at this level: the autoimmune response,
supported by the presence of polymorpho-
nuclear leukocytes in the inner ear and the
death of hair cells, and the deposition of
immune complexes in the vessels, as demon-
strated by the presence of vasculitis in the
inner ear and by atrophy of the stria
vascularis. An understanding of the aetio-
pathology of SLE through temporal bone
findings is certainly helpful in identifying the
most effective treatment for SLE in patients
with auditory and vestibular disorders. If we
assume that temporal bone findings are an
exact representation of SLE mechanisms, it
appears clear that although corticosteroid
therapy is still routinely used for hearing
disorders, future research will show that
monoclonal antibodies are the gold stand-
ard treatment for systemic and specific SLE-
related alterations such as inner ear damage.
The use of monoclonal antibodies is often
limited to cancer treatment because of their
high cost and financial impact on healthcare
systems. Although current findings are
encouraging, further studies involving larger
numbers of patients are necessary to better
define the correlations among clinical symp-
toms, temporal bone findings, and patho-
logical mechanisms in patients with SLE.
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